BioPharmSignal logoBioPharmSignal

Biotech News

Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

Pulmonx (LUNG)PulmonxEarnings

REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Wednesday,

Related news

LUNGPulmonx2026-07-29 20:05 EST

Pulmonx Reports Second Quarter 2026 Financial Results

ANGOAngioDynamics2026-10-08 10:02 EST

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

IRIXIRIDEX2026-08-04 20:05 EST

Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026

STIMNeuronetics2026-07-28 12:30 EST

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

TMCITreace Medical Concepts2026-07-24 11:05 EST

Treace to Report Second Quarter 2026 Financial Results on August 7, 2026

HYPRHyperfine2026-10-08 11:30 EST

Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026

IARTIntegra LifeSciences2026-10-06 12:30 EST

Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026

RMDResMed2026-10-01 20:05 EST

Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026

ANGOAngioDynamics2026-09-28 20:30 EST

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

View all latest news

Pulmonx

Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung...

Recent company news

LUNGPulmonx2026-09-01 20:05 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-08-27 20:05 EST

Pulmonx to Participate in Upcoming Investor Conferences

LUNGPulmonx2026-07-29 20:05 EST

Pulmonx Reports Second Quarter 2026 Financial Results

LUNGPulmonx2026-07-28 20:05 EST

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

LUNGPulmonx2026-07-15 20:05 EST

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

Stock data

Close
1.78 USD
Market cap
68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States